CymaBay Therapeutics Inc (NASDAQ:CBAY)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $7.37 and last traded at $9.60, with a volume of 3132726 shares. The stock had previously closed at $10.50.

Several equities analysts recently issued reports on the company. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 7th. Cantor Fitzgerald set a $17.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 7th. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 5th. BidaskClub upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Finally, Piper Jaffray Companies boosted their price target on CymaBay Therapeutics to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 10th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. CymaBay Therapeutics currently has an average rating of “Buy” and a consensus target price of $21.75.

The company has a market cap of $687.12 million, a PE ratio of -11.41 and a beta of 1.89.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). As a group, analysts forecast that CymaBay Therapeutics Inc will post -1.26 earnings per share for the current fiscal year.

In related news, CEO Sujal Shah acquired 5,000 shares of the stock in a transaction dated Monday, October 15th. The shares were bought at an average cost of $9.90 per share, for a total transaction of $49,500.00. Following the purchase, the chief executive officer now owns 100,000 shares in the company, valued at approximately $990,000. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in CymaBay Therapeutics by 246.8% during the 2nd quarter. BlackRock Inc. now owns 4,054,285 shares of the biopharmaceutical company’s stock worth $54,410,000 after acquiring an additional 2,885,082 shares during the last quarter. Eagle Asset Management Inc. bought a new stake in CymaBay Therapeutics during the 2nd quarter worth approximately $27,686,000. Carillon Tower Advisers Inc. bought a new stake in CymaBay Therapeutics during the 2nd quarter worth approximately $19,422,000. Baker BROS. Advisors LP grew its position in CymaBay Therapeutics by 25.5% during the 2nd quarter. Baker BROS. Advisors LP now owns 4,917,700 shares of the biopharmaceutical company’s stock worth $65,996,000 after acquiring an additional 1,000,000 shares during the last quarter. Finally, Voya Investment Management LLC bought a new stake in CymaBay Therapeutics during the 2nd quarter worth approximately $12,667,000. Institutional investors own 95.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/11/13/cymabay-therapeutics-cbay-sets-new-12-month-low-at-7-37.html.

CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

See Also: What is intrinsic value?

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.